Enpurte nan asid amine yo itilize pou sentèz pwoteyin
Detay Product
| NO | Pwodwi | Cas non | Endikatè bon jan kalite kle | |||
| Pite | Max. salte | Total rezidi sòlvan | Imidite | |||
| 1 | FMOC-β-ala-ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 2 | Fmoc-d-ala-d-ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 3 | FMOC-β-ala-d-ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 4 | FMOC-ARG (PBF) -Arg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 5 | FMOC-β-ala-arg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 6 | FMOC-D-ARG (PBF) -D-ARG (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 7 | FMOC-β-ala-d-arg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 8 | FMOC-HOMOARG (PBF) -HOMOARG (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 9 | FMOC-β-Ala-omoarg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 10 | FMOC-ASN (TRT) -Asn (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 11 | FMOC-β-ALA-ASN (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 12 | FMOC-ASP (OTBU) -Asp (OTBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 13 | FMOC-β-Ala-Asp (OTBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 14 | FMOC-CYS (TRT) -CYS (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 15 | FMOC-β-Ala-Cys (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 16 | FMOC-CYS (ACM) -cys (ACM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 17 | FMOC-β-Ala-Cys (ACM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 18 | FMOC-GLN (TRT) -GLN (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 19 | FMOC-β-Ala-Gln (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 20 | FMOC-Glu (OTBU) -glu (OTBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 21 | FMOC-β-ala-glu (OTBU) -OH.H2O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 22 | FMOC-β-ala-gly-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 23 | Fmoc-li (trt) -his (trt) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 24 | FMOC-β-ala-li (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 25 | FMOC-ILE-ILE-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 26 | FMOC-β-Ala-Ile-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 27 | Fmoc-leu-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 28 | FMOC-β-ala-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 29 | Fmoc-d-leu-d-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 30 | FMOC-β-ala-d-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 31 | FMOC-LYS (BOC) -LYS (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 32 | FMOC-β-ala-lys (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 33 | Fmoc-lys (alloc) -lys (alloc) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 34 | FMOC-β-ala-lys (alloc) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 35 | FMOC-Met-Met-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 36 | FMOC-β-ala-met-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 37 | FMOC-ORN (BOC) -orn (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 38 | FMOC-β-ala-Orn (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 39 | Fmoc-phe-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 40 | FMOC-β-Ala-Phe-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 41 | Fmoc-d-phe-d-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 42 | FMOC-β-Ala-D-Phe-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 43 | Fmoc-pro-pro-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 44 | FMOC-β-ala-pro-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 45 | Fmoc-ser (tbu) -ser (tbu) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 46 | FMOC-β-ala-ser (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 47 | FMOC-SER (TRT) -SER (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 48 | FMOC-β-ala-ser (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 49 | Fmoc-thr (tbu) -Thr (tbu) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 50 | FMOC-β-ala-th (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 51 | FMOC-TRP (BOC) -TRP (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 52 | FMOC-β-ALA-TRP (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 53 | FMOC-D-TRP (BOC) -D-TRP (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 54 | FMOC-β-ala-D-trp (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 55 | FMOC-TYR (TBU) -TYR (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 56 | FMOC-β-Ala-Tyr (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 57 | FMOC-D-TYR (ET) -D-TYR (ET) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 58 | FMOC-β-Ala-D-Tyr (ET) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 59 | Fmoc-tyr (mwen) -Tyr (mwen) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 60 | FMOC-β-Ala-Tyr (ME) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 61 | Fmoc-val-val-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 62 | FMOC-β-Ala-Val-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 63 | FMOC-D-CIT-D-CIT-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 64 | FMOC-β-ala-d-cit-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 65 | FMOC-β-ala-dab-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 66 | Fmoc- (3- (2-naphyl) -d-ala) 2-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 67 | FMOC-β-ALA-3- (2-naphyl) -d-ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 68 | Fmoc- (3- (3-piridinil) -d-ala) 2-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 69 | FMOC-β-ALA-3- (3-piridinil) -D-Ala-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 70 | Fmoc- (4-kloro-d-phe) 2-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 71 | FMOC-β-ALA-4-chloro-d-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 72 | FMOC- (D-4APH (TBUCBM)) 2-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 73 | FMOC-β-Ala-D-4APH (TBUCBM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 74 | Fmoc-aPh (l-hor) -aph (l-hor) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 75 | FMOC-β-Ala-APH (L-HOR) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 76 | FMOC-LYS (IPR, BOC) -lys (IPR, BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 77 | FMOC-β-ala-lys (IPR, BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 78 | FMOC-β-ala-aea-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 79 | Fmoc-aib-aib-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 80 | FMOC-β-ala-aib-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 81 | Fmoc-arg-oh | 91000-69-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 82 | H-arg (PBF) -OH | 200115-86-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 83 | Fmoc-d-arg-oh | 130752-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 84 | HD-Arg (PBF) -OH | 200116-81-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 85 | Fmoc-homoarg-oh.hcl | 208174-14-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 86 | H-omoarg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 87 | Fmoc-d-omoarg-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 88 | HD-homoarg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 89 | Fmoc-asn-oh | 71989-16-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 90 | H-ASN (TRT) -OH | 132388-58-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 91 | FMOC-ASP-OH | 119062-05-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 92 | H-Asp (OTBU) -OH | 3057-74-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 93 | Fmoc-cys-oh | 135248-89-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 94 | H-Cys (TRT) -OH | 2799/7/7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 95 | H-Cys (ACM) -OH.HCL | 28798-28-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 96 | Fmoc-gln-oh | 71989-20-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 97 | H-Gln (TRT) -OH | 102747-84-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 98 | Fmoc-glu-oh | 121343-82-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 99 | H-glu (OTBU) -OH.H2O | 2419-56-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 100 | Fmoc-li-oh | 116611-64-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 101 | H-li (TRT) -OH | 35146-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 102 | Boc-li-oh | 17791-52-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 103 | Fmoc-lys-oh | 105047-45-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 104 | H-lys (Boc) -OH | 2418-95-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 105 | H-lys (alloc) -OH | 6298/3/9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 106 | FMOC-ORN-OH.HCL | 201046-57-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 107 | H-Orn (Boc) -OH | 13650-49-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 108 | Fmoc-ser-oh | 73724-45-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 109 | H-Ser (TBU) -OH | 18822-58-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 110 | H-Ser (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 111 | Fmoc-thr-oh.h2o | 73731-37-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 112 | H-th (TBU) -OH | 4378-13-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 113 | Fmoc-trp-oh | 35737-15-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 114 | H-trp (Boc) -OH | 146645-63-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 115 | Fmoc-d-trp-oh | 86123-11-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 116 | HD-TRP (BOC) -OH | 201290-11-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 117 | Fmoc-tyr-oh | 92954-90-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 118 | H-Tyr (TBU) -OH | 18822-59-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 119 | FMOC-D-TYR-OH | 112883-29-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 120 | HD-TYR (ET) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 121 | H-tyr (m) -oh.hcl | 67423-44-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 122 | FMOC-D-4APH (CBM) -OH | 324017-22-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 123 | HD-4APH (TBUCBM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 124 | FMOC-LYS (IPR) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 125 | H-lys (IPR, Boc) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
De
Konpansasyon
Gentolex bay bon jan kalite gwo pwodwi, si se nenpòt ki bon jan kalite pwodwi leve soti vivan nan kliyan an nan tan ki nesesè yo ak prèv ase, nou pral bay analiz ki nesesè yo ak evalyasyon yo deklanche pwosedi yo nan konpansasyon.
Prodiksyon
Kapasite yo nan pwodwi pharmaceutique rive nan klas tòn, kapasite yo nan pwodwi chimik rive nan 100tons+ klas, kapasite yo yo byen ekipe sèvi kliyan atravè lemond.
Rechèch ak Devlopman
Chak ane, gen plan mete kanpe pa ekip la R & D yo devlope diferan nouvo pwodwi, lè objektif mete, chak manm nan ekip la ap gen yo pote sou ak KPI responsablite ak ak politik ankourajman.
